Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications by Mbui, Jennifer M. et al.
Mbui, Jennifer M. and Oluka, Margaret N. and Guantai, Eric M. and Sinei, 
Kipruto A. and Achieng, Loice and Baker, Amanj and Jande, Mary and 
Massele, Amos and Godman, Brian (2017) Prescription patterns and 
adequacy of blood pressure control among adult hypertensive patients 
in Kenya; findings and implications. Expert Review of Clinical 
Pharmacology, 10 (11). pp. 1263-1271. ISSN 1751-2441 , 
http://dx.doi.org/10.1080/17512433.2017.1371590
This version is available at https://strathprints.strath.ac.uk/61625/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
1 
 
Prescription patterns and adequacy of blood pressure control among adult hypertensive 
patients in Kenya; findings and implications 
 
JENNIFER M. MBUI1, MARGARET N. OLUKA1, ERIC M. GUANTAI1, KIPRUTO A. SINEI1, LOICE 
ACHIENG2, AMANJ BAKER3, MARY JANDE4, AMOS MASSELE5, *BRIAN GODMAN3,6,7 
 
1Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, P.O 
Box 19676-00202, Nairobi, Kenya. Email: mbuijennifer@gmail.com; olukamarga@yahoo.com, 
eguantai@uonbi.ac.ke;  sinei@uonbi.ac.ke  
2Department of Medicine, University of Nairobi, Nairobi, Kenya. Email: loicea.la@gmail.com 
3Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University, Glasgow, UK. 
Emails: Brian.godman@strath.ac.uk; amanj.baker@strath.ac.uk 
4School of Pharmacy, Catholic University of Health and Allied Science, P.O. Box 1464, Mwanza, 
Tanzania. Emails: maryjande@gmail.com 
5Department of Clinical Pharmacology, School of Medicine, University of Botswana, Gaborone, 
Botswana. Email: amos.massele@mopipi.ub.bw   
6Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, 
Karolinska University Hospital Huddinge, Stockholm, Sweden. Email: Brian.Godman@ki.se 
7Health Economics Centre, Liverpool University Management School, Liverpool University, UK. Email: 
Brian.Godman@liverpool.ac.uk  
 
*Author for correspondence. Division of Clinical Pharmacology, Karolinska Institute, Karolinska 
University Hospital Huddinge, SE-141 86, Stockholm, Sweden. Email: Brian.Godman@ki.se. 
Telephone + 46 8 58581068. Fax + 46 8 59581070 and Strathclyde Institute of Pharmacy and 
Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, United Kingdom. Email:  
brian.godman@strath.ac.uk. Telephone: 0141 548 3825. Fax: 0141 552 2562 
 
(Accepted for publication ± Expert Review of Clinical Pharmacology. Please keep CONFIDENTIAL). 
 
ABSTRACT 
 
Introduction: Hypertension is a major cause of global morbidity and mortality, with high prevalence rates 
in Africa including Kenya. Consequently, it is imperative to understand current treatment approaches 
and their effectiveness in practice. Currently, there is paucity of such data in Kenya, which is a concern. 
The aim is to describe prescribing patterns and adequacy of blood pressure control in adult hypertensive 
patients to guide future practice. Method: Retrospective study of patients attending a sub-county 
outpatient clinic combined with qualitative interviews. Results: 247 hypertensive patients, predominantly 
female, mean age 55.8 years on antihypertensive therapy for 1-5 years, were analyzed. ACEIs and 
thiazide diuretics were the most commonly prescribed mainly as combination therapy. Treatment 
typically complied with guidelines, mainly for stage 2 hypertension (75%). BP control was observed in 
46% of patients, with a significant reduction in mean systolic (155 to 144 mmHg) and diastolic (91 to 83 
mmHg) BP (P<0.001). 3DWLHQWVRQDQWLK\SHUWHQVLYHGUXJVZHUHPRUHOLNHO\WRKDYHXQFRQWUROOHG%3
(OR:1.9, p=0.021). Conclusion: Encouragingly good adherence to guidelines helped by training. Poor 
blood pressure control in the majority needs to be addressed. Additional training of prescribers and 
follow-up of measures to improve BP control will be introduced and followed up. 
 
Key words: Hypertension, Prescribing patterns, treatment guidelines, antihypertensive medicines, 
Kenya 
 
1. INTRODUCTION 
 
The highest prevalence of hypertension worldwide is seen in the African region (1), with reported 
prevalence as high as 80% among those aged 50 or over (2, 3), which is set to rise (1), enhanced by 
growing rates of diabetes and obesity (4, 5). High rates are not helped by typically low levels of 
awareness, treatment, and control of hypertension among patients in Africa, including Kenya, 
exacerbated by low levels of medication adherence (1, 6, 7). In Kenya, the mean systolic blood pressure 
has increased from 127 to 132 mmHg between 1990 and 2008 (8). Overall prevalence rates of 
hypertension among adults in Kenya aged between 35 and 64 is approximately 30% (7). However, 
others have demonstrated higher rates of 50% or more (9, 10). Consequently, hypertension has 
emerged as a major global public health issue in Africa (11, 12) including Kenya.  
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Antihypertensive therapy has demonstrated clear benefits through reducing the risk of adverse health 
outcomes (13). The use of treatment guidelines typically enhances the appropriate use of medicines, 
although there are concerns with adherence rates to guidelines in practice across countries (14-18). 
The current Kenyan Standard Treatment Guidelines (STGs) recommend the use of diuretics, beta 
blockers, calcium channel blockers (CCDs), angiotensin converting enzyme inhibitors (ACEIs) and 
angiotensin receptor blockers (ARBs) for patients with hypertension. This is in line with Joint National 
Committee (JNC) Guidelines (19, 20), with treatment subsequently stepped up if blood pressure (BP) 
control is not being achieved.  However, there is stronger recommendation of a thiazide diuretic or a 
CCB initially in the JNC guidelines (19, 20) compared with the Kenyan STGs, which recommend ACEIs 
as first line therapy (21), potentially leading to under use of CCBs in Kenya   
 
To date, there is paucity of data on prescribing patterns of antihypertensive medicines in Kenya. This 
is a matter of concern considering the public health burden of hypertension in Kenya, and the serious 
patient consequences of poor control (1, 8, 10, 22). In addition, the few studies to date have  typically 
found only limited control of hypertension in Kenya, even in those patients taking anti-hypertensive 
medicines (23), at rates ranging from 3% to 33% of the adult population (9, 23-25).  
 
Consequently, we sought to ascertain current prescribing patterns of antihypertensive medicines in 
patients undergoing treatment for hypertension in Kenya, determine the level of compliance with 
treatment guidelines and subsequent adequacy of BP control, as well as identify key determinants of 
BP control among adult hypertensive patients.  The findings to provide future guidance to the Ministry 
of Health, and other authorities in Kenya, to improve future control of hypertension. 
 
Currently, there is also a scarcity of electronic health information systems in Kenya to monitor the care 
of patients in ambulatory care, unlike the situation for these patients with HIV included in the AMPATH 
programme; however, initiatives are in place to address this (26-30). The introduction of Access 
programmes to improve the availability of medicines to patients with chronic diseases in Kenya, such 
as those with hypertension, should further help in the development of such systems (31, 32) to address 
recognized deficiencies (33). As a result, the findings from this study can also be used as a baseline to 
further improve the management of this important disease as access to medicines improves for patients 
 
2. Materials and Methods 
 
2.1 Study locality 
The study was conducted at the medical out-patient clinic (MOPC) of Ruiru sub-county hospital in 
Kiambu County, Kenya.  Ruiru is one of the peri-urban satellite towns of Nairobi City with a community 
of mainly middle class socioeconomic status. The MOPC serves approximately 800 active hypertensive 
patients from both urban and rural areas. Prescribers at the MOPC consist of medical consultants, 
medical officers and clinical officers. Consequently, this can provide a reasonable representation of 
current treatment practices across MOPCs in Kenya. In addition, provide a baseline for the recent 
access programmes, with this MOPC one of the chosen sites.  
 
2.2 Study design 
A descriptive cross-sectional study was conducted between January to April 2015 to collect data on the 
current use of antihypertensive medicines and their rationale at the MOPC of Ruiru Sub-county hospital.  
A mixed-method approach was used to collect data whereby quantitative data were collected by 
UHWURVSHFWLYHDQDO\VLVRIPHGLFLQHVSUHVFULEHGIURPSDWLHQWV¶PHGLFDOUHFRUGVDWWKHLUODVWYLVLWXVLQJD
pre-designed and validated data collection form. A semi-structured interview guide was used for 
collecting qualitative data from prescribers at the MOPC, pre-tested to enhance the quality of data 
collection. Its content is described below.  
 
2.3 Study population 
The study population consisted of active, registered hypertensive patients aged 18 years and above, 
attending the MOPC at Ruiru Sub-County hospital for at least one year prior to the commencement of 
the study.  The patients were on treatment with at least one anti-hypertensive medicine, had visited the 
clinic at least three times in the year preceding the study period (January to April 2015) to demonstrate 
they had received routine management and had complete medical records.  Hypertensive patients were 
excluded if they had not visited the clinic at least three times in a year, were pregnant or had incomplete 
medical records. This is because it is normal practice in this clinic to review patients at least every three 
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to four months. The one year follow-up period was deemed adequate to provide enough treatment 
record to evaluate the management of hypertension at this facility. For the qualitative study, the study 
population consisted of all prescribers stationed at the MOPC at the time of the study.  
 
2.4 Sample size 
The sample size for this study was calculated according to the Cochran formula for sample size 
calculation for categorical variables (34). A previous study in Kenya had reported compliance to 
antihypertensive guidelines of 80% (35), which was used in sample size calculation as follows: n = z2 
(p) (q)/d2. Where:  
n = sample size 
z = z statistic for 95% level of confidence which is conventionally = 1.96  
p = estimated prevalence or proportion in the population 
q =1-p 
d = level of precision used in the study set at 5% 
  
A sample size of 246 was calculated from the above formula which was adjusted to cater for the 
proportion of files with incomplete data estimated at 10% to yield a sample size of 271.   
 
2.5 Sampling procedure  
Systematic purposive sampling was used to sample patients from a list of patients obtained from the 
patient attendance register for every clinic day of the four-month study period. Files belonging to the 
eligible sampled patients were retrieved from the records department until the required sample size was 
accrued.  Informed consent was obtained from the prescribers before enrolment into the study. Since 
only five prescribers were working at the MOPC during the period of data collection, all were 
interviewed.     
 
2.6 Data collection procedure 
A predesigned, validated data collection form was used to abstract quantitative data from the medical 
records of each patient. Data were collected on the following at recruitment into the study: patient 
demographic characteristics, comorbidities, BP, current antihypertensive medication and other 
FRQFXUUHQWPHGLFDWLRQVDV UHFRUGHG LQHDFKSDWLHQW¶V ILOHDW WKH ODVWYLVLWGXULQJ WKHVWXG\SHULRG ,Q
addition, the initial BP reading when the patient was registered at the clinic was determined 
retrospectively from the patient records and recorded.   
 
At Ruiru sub-county hospital, initial and subsequent blood pressure (BP) was typically recorded using 
a digital sphygmomanometer, and co-morbidities such as diabetes (defined as blood glucose > 7.8 
mmol/L on more than one occasion) were diagnosed as per the Kenyan STGs for the management and 
referral of common conditions (21). This information was typically recorded in the SDWLHQWV¶QRWHV and 
subsequently transferred to the data collection forms for analysis. There was no other source of clinical 
information. 
 
For the qualitative study, prescribers working at the study site were informed about the study including 
the expected duration of the interview, voluntary participation and confidentiality. On signing the consent 
form, the interview was conducted using a semi-structured interview guide. Data collected included 
SUHVFULEHUV¶ FDGUH approximate number of patients seen per clinic day (workload); awareness and 
adherence to treatment guidelines for hypertension; post-qualification training on the use of the 
guidelines; challenges encountered in their management of hypertensive patients; and barriers to their 
adherence to treatment guidelines. 
 
2.7 Data analysis 
Quantitative data were analysed using STATA 10 (StanCorp, Inc, Texas, and USA). All data were 
subjected to descriptive data analysis. Continuous variables were presented as means (SD) when 
normally distributed and as median (range) when not normally distributed. Categorical variables were 
presented as counts and percentages. Antihypertensive medicines were categorized according to their 
therapeutic classes. The frequency of each pharmacological class and that of individual medications 
were expressed as a percentage of the total number of prescriptions. Patients were categorized 
according to the levels of their systolic blood pressure (SBP) and diastolic blood pressure (DBP) at 
diagnosis and at the last visit according to the JNC-7 classification of hypertension (19) (Box 1). 
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Box 1 ± Grades of hypertension according to the JNC-7 classification of hypertension  
 
   Grades of hypertension                       SBP (mmHg)             DBP (mmHg) 
Normal BP                                             <120                            <80 
Prehypertension                                    120-139                     80-89 
Stage 1                                                  140-159                     90-99 
6WDJH 
,VRODWHGV\VWROLFK\SHUWHQVLRQ 
NB:SBP = systolic blood pressure, DBP = diastolic blood pressure 
 
Patients were also grouped according to the adequacy of their BP control.  Adequate BP control was 
defined as having the most recent reading of less than 140/90 mmHg in line with WHO guidance (1, 5).  
Bivariate analysis was done to compare subjects with controlled and those with un-controlled BP. 
Comparison of the distribution of variables across arms was done by Pearson chi-square test for 
categorical variables, or the unpaired t-test for continuous variables. Variables that were found 
significant in the bivariate analysis were then included in a multivariable logistic regression analysis to 
identify key independent variables influencing BP control.  P-values of 0.05 or less were considered as 
significant. 
 
Prescription patterns for treatment of hypertension at the study site were subsequently compared to 
both the JNC-8 management guidelines and the Kenyan STGs (21). However, for evaluating 
adherence, comparisons were undertaken to JNC 8 guidelines. JNC 8 guidelines were chosen as they 
were the most current, evidence-based guidelines at the time of the study, and represented a credible 
international benchmark for the management of hypertension. They were seen as more up-to-date than 
the Kenyan STGs, and gave specifications on black patients,  with the Kenyan STGs last revised in 
2009. For example, the Kenyan STG recommends the use of an ACEI in diabetic -hypertensive patients. 
However,    recent studies have failed to show the superiority of ACEIs over other treatments in the 
prevention of renal disease among black patients (36), reflected in JNC 8, which recommends the use 
of thiazide diuretics or CCBs as first-line therapy in black patients (19, 20). JNC8 is also seen as more 
relevant to Kenya than for instance NICE, ESH or CHEP recommendations in view of its comments on 
treating black hypertensive patients alongside being seen as more up-to-date (37, 38), The criteria for 
evaluation focused on choices of prescribed drugs, appropriate drug therapy for compelling indications, 
appropriate concurrent drugs and appropriate combination therapy and dosing.    
 
A qualitative review of interview responses was carried out through a descriptive analysis of key data 
from each participant.  Analysis was undertaken by discerning patterns or themes among responses 
from participants and performing meaningful groupings of the themes.  
 
2.8 Ethical consideration 
Approval to carry out the study was granted by the Kenyatta National Hospital / University of Nairobi 
Ethics Review Committee (KNH/UoN ERC).  Approval to conduct the study was also granted by the 
Hospital management. Patient records were identified by codes to maintain privacy and confidentiality.  
Informed consent was granted by all prescribers from whom qualitative data was collected.  
 
3. Results 
3.1 Baseline characteristics of study population 
Baseline characteristics of study population are shown in Table 1.  A total of 247 hypertensive patients 
were included in the study of which the majority, 216 (87%), were females.  The overall mean age of 
the hypertensive patients was 56 ± 12.5 years, with most of the patients being in the range of 40 to 59 
years (44%). Diabetes was the most common comorbidity among the hypertensive patients (37%). Most 
of the patients 178 (72%) had been on antihypertensive therapy for between one and five years.  
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Table 1: Baseline characteristics of hypertensive patients included in the study (N=247) 
 
Characteristics n % 
Sex 
   Male 
   Female  
 
31 
216 
 
12.6 
87.4 
Age (years) 
     20-39 
     40-59 
     60-79 
      
 
28 
109 
107 
3 
 
11.3 
44.1 
43.3 
1.2 
Comorbid conditions 
   Diabetes 
   Cardiovascular disease 
   Peripheral neuropathy 
  Asthma 
  HIV/AIDS 
  Arthritis  
   None  
 
91 
5 
6 
4 
1 
1 
139 
 
36.8 
2.0 
2.4 
1.6 
0.4 
0.4 
56.2 
Treatment duration 
   \HDU 
   >1 to 5 years 
   >5 to 10 years 
   >10 years 
 
63 
178 
4 
2 
 
25.5 
72.1 
1.6 
0.8 
 
3.2 Prescription patterns of antihypertensive drugs in the study population 
The most frequently prescribed class of antihypertensive drugs at the time of the visit was the ACEIs at 
48% followed by thiazide diuretics at 40% as shown in Table 2.  
 
Table 2: Antihypertensive medicines prescribed for hypertensive patients 
 
Class\ Drug Frequency % 
ACEIs 
   Enalapril 
119 
119 
48.2 
48.2 
ARBs 
   Losartan 
   Telmisartan 
67 
66 
1 
27.1 
26.7 
0.4 
CCBs 
   Nifedipine 
   Amlodipine 
64 
29 
35 
26.0 
11.7 
14.3 
BBs 
   Atenolol 
   Carvedilol  
   Propranolol 
71 
64 
4 
3 
28.7 
25.9 
1.6 
1.2 
Thiazide diuretics 
   Hydrochlorthiazide  
100 
100 
40.5 
40.5 
Other diuretics 
   Furosemide 
   Spironolactone 
12 
7 
5 
4.8 
2.8 
2.0 
Miscellaneous 
   Methyldopa  
   Hydralazine  
4 
2 
2 
1.6 
0.8 
0.8 
1%$&(,V $QJLRWHQVLQFRQYHUWLQJHQ]\PHLQKLELWRUV$5%V $QJLRWHQVLQUHFHSWRUEORFNHUV%%V ȕ
blockers, CCBs= Calcium channel blockers 
 
The antihypertensive regimens prescribed are shown in Table 3.  ACEIs were the most frequently 
prescribed monotherapy regimen, where they accounted for 20% of all prescriptions. A combination of 
an ACEI and a thiazide diuretic was the second most prescribed regimen at 14% of all prescriptions.  
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Most patients were either on monotherapy or on two-drug regimens at 40% and 44% respectively. 
Combination therapies accounted for approximately 60% of all prescriptions.   
 
Table 3: Specific regimens of antihypertensive drugs prescribed for the hypertensive patients 
 
Regimen Frequency  % 
Monotherapy 
ACEI 
ARB 
Beta blocker  
Thiazide diuretic 
CCB 
 
 
50 
21 
11 
9 
8 
 
 
20.2 
8.5 
4.5 
3.6 
3.2 
 
2-drug combination therapy 
Thiazide diuretic + ACEI 
Thiazide diuretic + BB  
CCB + ACEI 
Thiazide diuretic + ARB 
CCB + ARB 
CCB + Thiazide diuretic 
CCB + BB 
 
 
35 
15 
12 
12 
11 
6 
6 
 
14.2 
4.9 
4.5 
2.4 
14.2 
4.9 
6.1 
3-drug combination therapy 
BB + Thiazide diuretic + ACEI 
BB + Thiazide diuretic + ARB  
CCB + BB + Thiazide diuretic 
CCB +ACEI + Thiazide diuretic 
CCB + BB + ACEI 
CCB + ARB + Thiazide diuretic 
CCB + BB +ARB  
 
 
7 
7 
5 
3 
3 
2 
2 
 
 
2.8 
2.8 
2.0 
1.2 
1.2 
0.8 
0.8 
NB: ACEI= Angiotensin converting enzyme Inhibitor, ARB= Angiotensin receptor blocker, BB= Beta 
blocker, CCB= Calcium channel blocker 
 
Prescription patterns of co-medications to the hypertensive patients are shown in Table 4. Metformin 
and glibenclamide were the most common at 29% and 23% respectively.   
 
Table 4: Co-medications prescribed for the hypertensive patients 
 
Class/ Drug  Frequency % 
Antidiabetics  
   Metformin 
   Glibenclamide 
   Insulin 
   Glimepiride 
 
71 
57 
13 
1 
 
28.7 
23.1 
5.3 
0.4 
Statins 
   Atorvastatin 
 
11 
 
4.4 
Antiplatelets 
   Aspirin  
 
22 
 
8.9 
NSAIDs 
   Meloxicam 
   Diclofenac 
   Naproxen 
 
14 
1 
1 
 
5.7 
0.4 
0.4 
Antiasthmatics 
   Salbutamol inhaler 
   Salbutamol tablets 
 
2 
2 
 
0.8 
0.8 
Antihistamines 6 2.4 
Antibiotics 
Supplements  
8 
13 
3.2 
5.3 
NB: NSAIDs= Non-steroidal anti-inflammatory drugs 
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3.3 Compliance of prescribing patterns to JNC-8 hypertension treatment guidelines 
Compliance to the JNC-8 treatment guidelines was high at 82% of prescriptions. Most prescribers 
complied with recommendations by the JNC- 8 report on the choice of antihypertensives for specific 
stages of hypertension, compelling indications, and use of appropriate concurrent medicines.  For 
example, use of appropriate drug therapy for compelling indications met guideline requirements in all 
cases (100%). For most prescribers, the rate of prescribing appropriate dosing and appropriate 
concurrent medicines was high at 96.4 and 95.4% respectively. However, compliance with treatment 
for stage 2 hypertension was 75.2% and for stage 1 lower at only 45.1%.   
 
3.4 Control of blood pressure levels among hypertensive patients 
Overall, 46% of the hypertensive patients in the study attained adequate blood pressure control, i.e. BP 
below 140/90 mmHg at the last clinic visit.  There was typically a reduction in mean BP levels from 
diagnosis to the last clinic visit (Table 5).  There was also a significant reduction in mean systolic blood 
pressure from 155 mmHg at diagnosis to 141 mmHg at the last clinic visit (P < 0.001). Similarly, the 
mean diastolic blood pressure was significantly reduced from 91 mmHg at diagnosis to 83 mmHg at the 
last visit (P < 0.001).  There was also a significant reduction in the number of patients in all stages of 
hypertension at the last visit with 7% having attained normal BP whereas those in stage 2 hypertension 
were significantly reduced from 43% to 19% at the last visit (P <0.001).  
 
Table 5: Control of blood pressure levels among hypertensive patients 
 
Description At Diagnosis         At the last visit   P value*        
Systolic blood pressure (mmHg) 
   Mean (SD) 
    
 
155 (20.4) 
 
 
141 (20.5)             <0.001 
 
Diastolic blood pressure (mmHg) 
   Mean (SD) 
    
 
91 (10.7) 
 
 
83 (10.5)              <0.001 
 
Staging   n (%) 
    Normal BP 
    Prehypertension 
    Stage 1 hypertension 
    Stage 2 hypertension 
 
Isolated Systolic Hypertension 
  Stage 1 ISH   
  Stage 2 ISH                                          
 
0 (0) 
27 (11.0) 
115 (46.5) 
105 (42.5) 
 
90 (36.4) 
58 (23.5) 
32 (13.0) 
 
18 (7.3)               <0.001 
96 (38.9) 
86 (34.8) 
47 (19.0) 
 
67 (27.1)             <0.001 
43 (17.4)             <0.001 
24 (9.4) 
NB: SD= Standard deviation, BP=blood pressure, n=frequency 
*The unpaired t-test was used for comparison of systolic and diastolic BP while chi-square test was 
used for comparison between the stages of hypertension 
 
3.5 Factors affecting blood Pressure control in hypertensive patients 
On bivariate analysis, some of the factors found to be significantly associated with poor BP control 
included the sex of the patient, the number of medicines they were prescribed and being on a beta 
blocker (Table 6). In the multivariable logistic regression analyses, all the included variables, except for 
being on beta-blockers, were independent risk factors for poor BP control. Females DQGSDWLHQWVRQ
antihypertensive drugs were approximately two times more likely to have uncontrolled BP (OR: 2.3, 
95%CI: 1.03, 5.1, p=0.043) and (OR:1.9, 95%CI: 1.1, 3.3, p=0.021), respectively. 
 
 
  
8 
 
Table 6: Factors affecting blood pressure control in hypertensive patients 
 
Characteristic  Total 
 
   N 
Blood pressure 
controlled, 
n (%) 
Blood pressure 
uncontrolled, 
n (%) 
OR  
(95% CI) 
P value 
Sex 
   Male 
   Female 
 
31 
216 
 
20 (64.5) 
94 (43.5) 
 
11 (35.5) 
122 (56.5) 
 
1 
2.4 (1.1-5.2) 
 
 
0.028 
Age 
   <60 years 
   \HDUV 
 
137 
110 
 
64 (46.7) 
50 (45.5) 
 
73 (53.3) 
60 (54.5) 
 
1 
1.1 (0.6-1.7) 
 
 
0.843 
Treatment duration 
   1 year 
   >1 year 
 
63 
184 
 
30 (47.6) 
84 (45.7) 
 
33 (52.4) 
100 (54.3) 
 
1 
1.1 (0.6-1.9) 
 
 
0.787 
Number of 
antihypertensives 
   1 
   2 
    
    
 
 
100 
147 
 
 
 
 
57 (57) 
57 (38.8) 
 
 
 
 
43 (43) 
90 (61.2) 
 
 
 
 
1 
2.1 (1.2, 3.7) 
  
 
 
 
0.005 
On a thiazide diuretic 
   Yes 
   No 
 
100 
147 
 
43 (43) 
71 (48.3) 
 
57 (57) 
76 (51.7) 
 
1.2 (0.7-2.1) 
1 
 
0.412 
On a CCB 
   Yes 
   No 
 
64 
183 
 
27 (42.2) 
87 (47.5) 
 
37 (57.8) 
96 (52.5) 
 
1.2 (0.7-2.2) 
1 
 
0.460 
On an ACEI 
   Yes  
   No 
 
119 
128 
 
60 (50.4) 
54 (42.2) 
 
59 (49.6) 
74 (57.8) 
 
0.7 (0.4-1.2) 
1 
 
0.195 
On an ARB 
   Yes 
   No 
 
67 
180 
 
25 (37.3) 
89 (49.4) 
 
42 (62.7) 
91 (50.6) 
 
1.6 (0.9-2.9) 
1 
 
0.089 
On a BB 
   Yes 
   No 
 
71 
176 
 
25 (35.2) 
89 (50.6) 
 
46 (64.8) 
87 (49.4) 
 
1.8 (1.1-3.3) 
1 
 
0.028 
Diabetic 
   Yes 
   No 
 
91 
156 
 
41 (45.1) 
73 (46.8) 
 
50 (54.9) 
83 (53.2) 
 
1.1 (0.6-1.8) 
1 
 
0.791 
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BB - beta blocker; 
CCB: calcium channel blocker;  
 
3.6 Adherence to hypertension treatment guidelines by prescribers  
Five prescribers were interviewed of whom three were females aged 20 to 40 years (mean 30 years). 
This consisted of three medical officers, one clinical officer and one consultant physician treating 10 to 
50 hypertensive patients per clinic day. Prescribers reported a great degree of awareness of the 
available hypertension treatment guidelines, namely JNC-7, JNC-8 and the Kenya Standard Treatment 
Guidelines (STG). All the prescribers had been trained on the use of the guidelines and appeared 
adherent. The most common challenges expressed by prescribers in the management of hypertension 
was poor patient adherence to medications, costly medications, medication stock outs, lack of patient 
counseling and support systems and the lack of laboratory and imaging facilities for further patient 
investigations.  
 
4. Discussion 
 
The demographic characteristics observed in this study were similar to those reported in other Kenyan 
studies (23, 39), with tKHKLJKQXPEHURIIHPDOHV7DEOHWKRXJKWWRUHÀHFWbetter health seeking habits 
of females in general versus males (40).  The mean age of 55.8 years (Table 1) is consistent with a 
previous  study in Kenya (35).  
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Diabetes was the most common comorbidity (Table 1), which was not surprising since hypertension 
and diabetes frequently coexist due to similar range of risk factors (19). This makes the management 
of hypertension extremely important in Kenya as poor BP control increases mortality in patients with 
diabetes (41). 
 
Overall there was good compliance to treatment guidelines (JNC-8) at 82%, mirroring a previous study 
in Kenya  (20), which is encouraging. Deviations from the guidelines were mostly observed in the 
treatment of Stage 1 hypertension, where only 45% of patients were treated according to the 
recommendations of JNC-8.  This could be due to clinical inertia (42) due to consideration of SDWLHQWV¶ 
circumstances including increasing the pill burden (6, 43, 44). This will be followed up in future studies. 
Prescribers also pointed out a lack of laboratory and imaging facilities for further patient investigations, 
which could also impede appropriate intensification of therapy.    
 
We believe the high use of ACEIs (Table 2), and under use of CCBs (prescribed in only 26% of patients), 
can be attributed to prescribers applying the recommendations of the Kenyan STG rather than those of 
JNC-8, with most prescribers undergoing training of the Kenyan STGs and applying these in their 
clinical practice. The observed high use of thiazide diuretics (Table 2) is though consistent with current 
recommendations in the JNC guidelines, especially in black patients (19, 20).  
 
Most patients were on monotherapy or 2-drug regimens (Table 3), with combination therapies 
accounting for approximately 60% of all prescriptions, similar to study carried out in India (45). The high 
rate of monotherapy FRXOGSRWHQWLDOO\EHH[SODLQHGE\SUHVFULEHUV¶UHOXFWDQFHWRLQWHQVLI\WKHUDS\GXH
to a number of factors, similar to other studies (42), and will be explored further.  We also observed that 
anti-diabetic drugs and low-dose aspirin were the most commonly prescribed concurrent medications 
(Table 4), no doubt due to the high prevalence of diabetes and CV disease among our hypertensive 
patients (Table 1), with aspirin recommended for secondary prevention of CV events in these patients 
(43).  
 
However, despite good compliance with treatment guidelines, BP was controlled in less than half of the 
hypertensive patients in this study (Table 5), below WHO recommendations (46).  This rate though is 
higher than that reported in other Kenyan studies (9, 23-25, 39), but similar to Zimbabwe (5), This is 
encouraging given concerns with the prescribing two or more anti-hypertensives and current high co-
payments for medicines for some patients.  Even though adherence was not monitored in our study, 
most of our patients were on one or two-drug regimens, which could have promoted good adherence 
(44, 47). However, this could be at the expense of achieving adequate BP control. 
 
Poor BP control in our study was strongly associated with sex whereby females were more likely to 
have poor control (Table 6),  in contrast though to other African studies (1), despite potentially having 
better health seeking behaviour However, it should be noted that our study population was 
predominantly female with only a small proportion (13%) male. 
 
Other studies in Kenya have attributed poor BP control to old age, having diabetes and being on three 
or more drugs (23, 39).  However, our study did not observe any association between poor BP control 
with age or diabetes, possibly because almost half of our patient population were below 60 years and 
did not have diabetes (Table 6).  We observed though an association between multi-drug regimens and 
poor BP control. Twenty nine patients (12%) in our study population were on a three- drug regimen 
(Table 3), with a high proportion 21(76% of these) being uncontrolled (data not shown). This could be 
explained by the difficulties patients face with adherence to multiple medications as observed in the 
study by Achieng et al (25).  We also postulate that patients who needed multi-drug regimens could 
have had more severe, resistant or refractory hypertension, which is inherently poorly controlled (20). 
Poor BP control may also be due to underuse of CCBs and over use of ACEIs and ARBs in our study 
patients (Table 3), with the ALLHAT study showing that both thiazide diuretics and CCBs have a greater 
effect on controlling BP versus ACEIs in African Americans (36). Co-payments for multiple medicines 
could also be an issue affecting adherence rates (48-52). This should be helped by Access programmes 
in Kenya in the future (31, 32) 
 
5. Study Limitations 
 
:HDFNQRZOHGJHWKDWWKHUHWURVSHFWLYHGDWDXVHGIRUWKLVVWXG\REWDLQHGIURPSDWLHQWV¶UHFRUGVPD\QRW
always be accurate and complete. In addition, we only used one study site, which may not be totally 
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representative of other MOPCs in Kenya. The actual protocol followed by healthcare professionals in 
WKHRVFLOORPHWULFPHDVXUHPHQWRISDWLHQWV¶%3ZDVDOVRQRWRXWOLQHGLQSDWLHQWV¶ notes. Consequently, 
techniques may have varied among the professionals at this site, and we had no way of verifying this. 
In addition, only prescription and comorbidity data was used to examine compliance to treatment 
guidelines, which may not always be reliable.  
 
Other factors which could affect the adequacy of BP control that were not considered include actual 
adherence to treatment in practice, accessibility to prescribed medicines, awareness and level of patient 
knowledge concerning the medicines prescribed, the need for proper BP control as well as other 
demographic characteristics such as the level of education and socioeconomic status. Furthermore, the 
small number of healthcare providers at the facility, with each attending to many patients, does mean 
that individual provider practices can significantly influence the overall standard of care observed at the 
facility. These factors will be addressed in future studies. Nevertheless, we believe our study is a good 
basis for suggesting future initiatives to improve the management of patients with hypertension in Kenya 
given the growing prevalence rates alongside the recent Access programmes. 
 
6. Conclusion and recommendations 
 
Prescribing patterns of antihypertensive drugs in this study were consistent with the Kenyan STGs,   
where most patients were on ACEIs and thiazide diuretics. Compliance to the latest treatment JNC 
guidelines was also found to be reasonably high in this MOPC, though there were deviations in the 
treatment of stage 1 hypertension. This high level of compliance to treatment guidelines could 
contribute positively to BP control although an appreciable number of patients were still not 
adequately controlled, especially female patients. However, the observed gap in adherence to 
guideline recommendations provides an avenue for future interventions. Incongruences noted 
between recommendations in international guidelines (JNC 7 and 8) and the local Kenyan guidelines 
should also be remedied through the timely updating of local STGs to avoid confusion and improve 
future care. Confusion has been seen in other settings and countries when there is conflicting advice, 
and should be avoided if possible (53). Treatment guidelines should be reviewed to reflect for 
instance the growing evidence showing superiority of chlorthalidone over hydrochlorthiazedine (54, 
55), although others are less sure (56). We will be monitoring this in the future. 
 
Issues of co-payment may have impacted on the number of medicines prescribed and hence 
adequate control. However, it is difficult to substantiate this without further studies. Co-payments 
could be reduced following the Access initiatives, and this will be monitored further in this MOPC and 
other sites in Kenya. These schemes can also include training healthcare workers to provide 
appropriate care. Additional research is also needed to address other possible determinants of BP 
control such as medication adherence, which was not the subject of this research.  
 
In the meantime, regular training of health workers on appropriate treatment guidelines is 
recommended to keep them up to date with current trends as new evidence emerges including 
addressing issues of poor BP control when this occurs. Active implementation programs have helped 
reduce BP among patients in Kenya. This alongside continuing audits on the use of antihypertensive 
medicines among treatment clinics is necessary to improve future care given the high and growing 
prevalence of hypertension in Kenya. We are encouraged by publications showing improvements in 
BP control in countries that have instigated multiple policies over time. This includes the USA with the 
percentage of adults with controlled BP increasing from 31.5% in 1999 to 54.0% in 2014 (57), with a 
similar increase in Turkey (58),  
 
7. Expert Commentary 
 
The prevalence of hypertension, and current poor control, is a major public health concern in Kenya. 
This is not helped by concerns with knowledge among patients, treatment approaches and adherence 
rates in routine care for ambulatory patients. This study showed there was generally good compliance 
with JNC guidelines, which is encouraging. However, the contradictory advice in the current Kenyan 
STGs has led to higher use of ACEIs and lower use of CCBs. There are also an appreciable number 
of patients with uncontrolled BP, despite good adherence to the guidelines, due to a number of factors 
including potential co-payments, prescriber reluctance to intensify therapy if needed, as well as 
potentially under utilization of CCBs. Co-payments as well as healthcare professional training is being 
addressed through the Access programmes, and we will be monitoring their impact in future years to 
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help improve the management of patients with hypertension in Kenya. Potential improvements in 
electronic systems should also help, building on existing examples. 
 
8. Five year commentary 
 
It is likely that we will see improvements in the management of patients with hypertension in Kenya 
over the next five years with increasing access to medicines with the ongoing programmes to offer 
these at low prices to patients, as well as improved training of healthcare professionals and patients 
and better access to laboratory and imaging facilities. This includes addressing fears of dose and 
drug escalation if needed to achieve good control. It is also likely there will be improvements in 
electronic systems to better monitor the care of hypertensive patients. This will build on existing 
initiatives such as the AMPATH approach for HIV patients with or without concomitant hypertension, 
enhanced by ongoing Access programmes. In addition, more up-to-date and consistent Standard 
Treatment Guidelines in Kenya addressing current concerns. These combined factors, together with 
regular visits to ambulatory care clinics, will help to improve the management of patients with 
hypertension in Kenya especially among women. As a result, there should be appreciable reductions 
in the number of patients with uncontrolled hypertension in Kenya over the coming years, similar to 
other countries in recent years.  
 
9. Key points 
 
x Hypertension is a major issue across Africa, including Kenya, leading to high rates of avoidable 
morbidity and mortality 
 
x Prevalence rates as high as 55% have been observed in some populations in Kenya. In addition, 
the limited number of studies to date have shown limited control of hypertension, ranging from 3% 
to 33% of the adult population 
 
x In this study, there was good adherence to the JNC guidelines (82% of prescriptions), although 
there was high use of ACEIs and under-utilisation of CCBs. This may have contributed to lower 
than expected control of BP in only 46% of patients despite the high adherence rates to the 
guidelines 
 
x Limited intensification of therapy, possibly due to physician fears, as well as issues of co-
payments, may also have resulted in limited control of hypertension in practice in this study 
population 
 
x It is expected that the introduction of Access programmes in Kenya, helping to address issues of 
co-payments and physician training, as well as improved electronic systems, will help improve the 
management of hypertension in Kenya in the future. This will be monitored.  
 
Acknowledgments and conflicts of interest 
 
There was no external funding for this project and none of the authors have any conflicts of interest to 
declare 
 
10. References 
 
1. Kayima J, Wanyenze RK, Katamba A, Leontsini E, Nuwaha F. Hypertension awareness, 
treatment and control in Africa: a systematic review. BMC cardiovascular disorders. 2013;13:54. 
2. Lloyd-Sherlock P, Beard J, Minicuci N, Ebrahim S, Chatterji S. Hypertension among older 
adults in low- and middle-income countries: prevalence, awareness and control. International journal 
of epidemiology. 2014;43(1):116-28. 
3. Dzudie A, Kengne AP, Muna WF, Ba H, Menanga A, Kouam Kouam C, et al. Prevalence, 
awareness, treatment and control of hypertension in a self-selected sub-Saharan African urban 
population: a cross-sectional study. BMJ open. 2012;2(4). 
4. Cois A, Day C. Obesity trends and risk factors in the South African adult population. BMC 
obesity. 2015;2:42. 
12 
 
5. Goverwa TP, Masuka N, Tshimanga M, Gombe NT, Takundwa L, Bangure D, et al. 
Uncontrolled hypertension among hypertensive patients on treatment in Lupane District, Zimbabwe, 
2012. BMC research notes. 2014;7:703. 
6. Nielsen JO, Shrestha AD, Neupane D, Kallestrup P. Non-adherence to anti-hypertensive 
medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 
subjects. Journal of human hypertension. 2017;31(1):14-21. 
7. Olack B, Wabwire-Mangen F, Smeeth L, Montgomery JM, Kiwanuka N, Breiman RF. Risk 
factors of hypertension among adults aged 35-64 years living in an urban slum Nairobi, Kenya. BMC 
public health. 2015;15:1251. 
8. Werner ME, van de Vijver S, Adhiambo M, Egondi T, Oti SO, Kyobutungi C. Results of a 
hypertension and diabetes treatment program in the slums of Nairobi: a retrospective cohort study. 
BMC health services research. 2015;15:512. 
9. Mathenge W, Foster A, Kuper H. Urbanization, ethnicity and cardiovascular risk in a 
population in transition in Nakuru, Kenya: a population-based survey. BMC public health. 
2010;10:569-. 
10. Irazola VE, Gutierrez L, Bloomfield G, Carrillo-Larco RM, Dorairaj P, Gaziano T, et al. 
Hypertension Prevalence, Awareness, Treatment, and Control in Selected LMIC Communities: 
Results From the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases. Global heart. 
2016;11(1):47-59. 
11. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of 
hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23. 
12. WHO. A global brief on hypertension - silent killer, global public health crisis. World Health 
Day 2013. Available at URL: 
http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf?ua=1   
13. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health 
outcomes associated with various antihypertensive therapies used as first-line agents: a network 
meta-analysis. Jama. 2003;289(19):2534-44. 
14. Van Spall HG, Shanbhag D, Gabizon I, Ibrahim Q, Graham ID, Harlos K, et al. Effectiveness 
of implementation strategies in improving physician adherence to guideline recommendations in heart 
failure: a systematic review protocol. BMJ open. 2016;6(3):e009364. 
15. Boonstra E, Lindbaek M, Khulumani P, Ngome E, Fugelli P. Adherence to treatment 
guidelines in primary health care facilities in Botswana. Trop Med Int Health. 2002;7. 
16. Francke AL, Smit MC, de Veer AJE, Mistiaen P. Factors influencing the implementation of 
clinical guidelines for health care professionals: A systematic meta-review. BMC Medical Informatics 
and Decision Making. 2008;8:38-. 
17. Taba P, Rosenthal M, Habicht J, Tarien H, Mathiesen M, Hill S, et al. Barriers and facilitators 
to the implementation of clinical practice guidelines: A cross-sectional survey among physicians in 
Estonia. BMC health services research. 2012;12:455-. 
18. Donnellan C, Sweetman S, Shelley E. Health professionals' adherence to stroke clinical 
guidelines: a review of the literature. Health policy (Amsterdam, Netherlands). 2013;111(3):245-63. 
19. National High Blood Pressure Education P.  The Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda 
(MD): National Heart, Lung, and Blood Institute (US); 2004. 
20. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 
2014 evidence-based guideline for the management of high blood pressure in adults: report from the 
panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311(5):507-
20. 
21. MOMS. Ministry of Medical Services Kenya, Ministry of Public Health and Sanitation Kenya. 
Standard Treatment Guidelines for Management and Referral of Common Conditions at Levels 4-6: 
Hospitals. Pages 36-37. Available at URL: 
http://apps.who.int/medicinedocs/documents/s21000en/s21000en.pdf   
22. Oti SO, van de Vijver S, Gomez GB, Agyemang C, Egondi T, Kyobutungi C, et al. Outcomes 
and costs of implementing a community-based intervention for hypertension in an urban slum in 
Kenya. Bull World Health Organ. 2016;94(7):501-9. 
23. Mutua EM, Gitonga MM, Mbuthia B, Muiruri N, Cheptum JJ, Maingi T. Level of blood pressure 
control among hypertensive patients on follow-up in a Regional Referral Hospital in Central Kenya. 
The Pan African Medical Journal. 2014;18:278. 
24. Hendriks ME, Wit FWNM, Roos MTL, Brewster LM, Akande TM, de Beer IH, et al. 
Hypertension in Sub-Saharan Africa: Cross-Sectional Surveys in Four Rural and Urban Communities. 
PloS one. 2012;7(3):e32638. 
13 
 
25. Achieng L, Joshi M, Ogola EN, Karari E. Adequacy of blood pressure control and level of 
adherence with antihypertensive therapy. East African medical journal 2009;86(11):499-506. 
26. AMPATH. Leading with care. Available at URL: http://www.ampathkenya.org/  [ 
27. Keny A, Wanyee S, Kwaro D, Mulwa E, Were MC. Developing a National-Level Concept 
Dictionary for EHR Implementations in Kenya. Studies in health technology and informatics. 
2015;216:780-4. 
28. Subramanian S, Tangka F, Edwards P, Hoover S, Cole-Beebe M. Developing and testing a 
cost data collection instrument for noncommunicable disease registry planning. Cancer epidemiology. 
2016;45 Suppl 1:S4-s12. 
29. Were MC, Mamlin BW, Tierney WM, Wolfe B, Biondich PG. Concept dictionary creation and 
maintenance under resource constraints: lessons from the AMPATH Medical Record System. AMIA  
Annual Symposium proceedings. AMIA Symposium. 2007:791-5. 
30. Subramanian S, Kibachio J, Hoover S, Edwards P, Amukoye E, Amuyunzu±Nyamongo M et 
al Research for Actionable Policies:: implementation science priorities to scale up non±communicable 
disease interventions in Kenya. Journal of Global Health,. 2017; 7(1). Available at URL: 
http://jogh.org/documents/issue201701/jogh-07-010204.pdf  
31. Novartis. Kenya first country to launch 'Novartis Access', expanding affordable treatment 
options against chronic diseases. Oct 15 2015. Available at URL: 
https://www.novartis.com/news/media-releases/kenya-first-country-launch-novartis-access-
expanding-affordable-treatment   
32. Ogola E. Health Heart Africa - the Kenyan Experience. Available at URL: 
http://www.pascar.org/uploads/files/HEALTHY_HEART_AFRICA_Elijah_Ogola.pdf   
33. MoH. Republic of Kenya Ministry of Health. KENYA NATIONAL STRATEGY FOR THE 
PREVENTION AND CONTROL OF NON-COMMUNICABLE DISEASES 2015 to 2020. Available at 
URL: http://www.who.int/nmh/ncd-task-force/kenya-strategy-ncds-2015-2020.pdf  
34. Cochran W. Sampling Techniques, 3rd Edition. 1977. ISBN: 978-0-471-16240-7. Available at 
URL: http://eu.wiley.com/WileyCDA/WileyTitle/productCd-047116240X.html  [ 
35. Mwangi K. Prescription patterns in management of hypertension at Kenyatta National 
Hospital's Medical Outpatient Clinic. Available at URL: 
http://uonlibrary.uonbi.ac.ke/content/prescription-patterns-management-hypertension-kenyatta-
national-hospitals-medical-outpatie-1   
36. Wright JT, Probstfield JL, Cushman WC, Pressel S, Cutler JA, Davis BR, et al. ALLHAT 
FINDINGS REVISITED IN THE CONTEXT OF SUBSEQUENT ANALYSES, OTHER TRIALS AND 
META-ANALYSES. Archives of internal medicine. 2009;169(9):832-42. 
37. Finks S, Ripley TL. Sorting it out: what JNC 8 is and what it is not. Journal of managed care & 
specialty pharmacy. 2015;21(2):110-2. 
38. Stephan D, Gaertner S, Cordeanu EM. A critical appraisal of the guidelines from France, the 
UK, Europe and the USA for the management of hypertension in adults. Archives of cardiovascular 
diseases. 2015;108(8-9):453-9. 
39. Joshi MD, Ogola E, Karari E, et al. Adequacy of blood pressure control and level of 
adherence with antihypertensive therapy. East Afr Med J. 2009;86:499-506. 
40. Mufunda E, Albin B, Hjelm K. Differences in health and illness beliefs in zimbabwean men 
and women with diabetes. The open nursing journal. 2012;6:117-25. 
41. Tight blood pressure control and risk of macrovascular and microvascular complications in 
type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (Clinical research ed). 
1998;317(7160):703-13. 
42. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia 
is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 
(Dallas, Tex : 1979). 2006;47(3):345-51. 
43. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC 
Guidelines for the management of arterial hypertension: the Task Force for the management of 
arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of 
Cardiology (ESC). Journal of hypertension. 2013;31(7):1281-357. 
44. Vrijens B, Antoniou S, Burnier M, de la Sierra A, Volpe M. Current Situation of Medication 
Adherence in Hypertension. Frontiers in pharmacology. 2017;8:100. 
45. Khurshid F, Aqil M, Alam MS, et al. Antihypertensive Medication Prescribing Patterns In A 
University Teaching Hospital In South Delhi. IJPSR. 2012;3(7):2057-63. 
46. Weinehall L, Ohgren B, Persson M, Stegmayr B, Boman K, Hallmans G, et al. High remaining 
risk in poorly treated hypertension: the 'rule of halves' still exists. Journal of hypertension. 
2002;20(10):2081-8. 
14 
 
47. Fernandez-Arias M, Acuna-Villaorduna A, Miranda JJ, Diez-Canseco F, Malaga G. 
Adherence to Pharmacotherapy and Medication-Related Beliefs in Patients with Hypertension in 
Lima, Peru. PloS one. 2014;9(12):e112875. 
48. (DGG\07&RRN&/2¶'D\.%XUFK63&DQWUHOO&5+RZ3DWLHQW&RVW-Sharing Trends 
Affect Adherence and Outcomes: A Literature Review. Pharmacy and Therapeutics. 2012;37(1):45-
55. 
49. Sinnott SJ, Buckley C, O'Riordan D, Bradley C, Whelton H. The effect of copayments for 
prescriptions on adherence to prescription medicines in publicly insured populations; a systematic 
review and meta-analysis. PloS one. 2013;8(5):e64914. 
50. Barron J, Wahl P, Fisher M, Plauschinat C. Effect of Prescription Copayments on Adherence 
and Treatment Failure with Oral Antidiabetic Medications. Pharmacy and Therapeutics. 
2008;33(9):532-53. 
51. Barbui C, Conti V. Adherence to generic v. brand antidepressant treatment and the key role of 
health system factors. Epidemiology and psychiatric sciences. 2015;24(1):23-6. 
52. Simoens S, Sinnaeve PR. Patient co-payment and adherence to statins: a review and case 
studies. Cardiovascular drugs and therapy. 2014;28(1):99-109. 
53. Kibuule D, Mubita M, Naikaku E, Kalemeera F, Godman BB, Sagwa E. An analysis of policies 
for cotrimoxazole, amoxicillin and azithromycin use in Namibia's public sector: Findings and 
therapeutic implications. International journal of clinical practice. 2017;71(2). 
54. Barrios V, Escobar C. Which thiazide to choose as add-on therapy for hypertension? 
Integrated blood pressure control. 2014;7:35-47. 
55. Vongpatanasin W. Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic. 
Current opinion in cardiology. 2015;30(4):361-5. 
56. Dhalla IA, Gomes T, Yao Z, Nagge J, Persaud N, Hellings C, et al. Chlorthalidone versus 
hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. 
Annals of internal medicine. 2013;158(6):447-55. 
57. Yoon SS, Carroll MD, Fryar CD. Hypertension Prevalence and Control Among Adults: United 
States, 2011-2014. NCHS data brief. 2015(220):1-8. 
58. Sengul S, Akpolat T, Erdem Y, Derici U, Arici M, Sindel S, et al. Changes in hypertension 
prevalence, awareness, treatment, and control rates in Turkey from 2003 to 2012. Journal of 
hypertension. 2016;34(6):1208-17. 
 
